½ÃÀ庸°í¼­
»óǰÄÚµå
1586000

Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå : »ùÇà Ãë±Þ, »ùÇà À¯Çü, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

COVID-19 Detection PoC Kits Market by Sample Handling (RNA Extraction Systems), Sample Type (Nasal Swabs, Nasopharyngeal Swab, Oropharyngeal Swab), End-Use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 188 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀåÀº 2023³â¿¡ 33¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 36¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.70%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 53¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

COVID-19 Áø´Ü PoC(Point-of-Care) ŰƮÀÇ ¹üÀ§¿Í Á¤ÀÇ´Â ±âÁ¸ °Ë»ç½Ç ȯ°æ ¹Û¿¡¼­ ½Å¼ÓÇÏ°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ¿ªÇÒÀ» Æ÷°ýÇÕ´Ï´Ù. ÀÌ Å°Æ®´Â Äڷγª19 È®ÁøÀÚÀÇ ½Å¼ÓÇÑ ½Äº°°ú °Ý¸®¿¡ ÇʼöÀûÀ̸ç, °øÇ×, Á÷Àå, ÀÇ·á ½Ã¼³ µî ´Ù¾çÇÑ È¯°æ¿¡¼­ ½Ç½Ã°£ ÀÇ»ç°áÁ¤À» ÃËÁøÇÕ´Ï´Ù. Àû¿ë ¹üÀ§´Â ¿Üµý ³«ÈÄµÈ Áö¿ª¿¡¼­ µµ½Ã Á߽ɺαîÁö È®´ëµÇ¾î °øÁß º¸°Ç ´ëÀÀÀ» °­È­Çϰí Àü¿°À» °¨¼Ò½Ãŵ´Ï´Ù. ÃÖÁ¾ »ç¿ë ½ÃÀå¿¡´Â ÀÇ·á ½Ã¼³, °øÁß º¸°Ç ±â°ü, ¹Î°£ ±â¾÷, ¿©Çà ¹× ±³À° ºÐ¾ß°¡ Æ÷ÇԵǸç, °¢ ºÐ¾ß´Â ¹ßº´À» °ü¸®ÇÏ°í ¾ÈÀüÀ» º¸ÀåÇϱâ À§ÇØ È¿À²ÀûÀÎ °Ë»ç ¼Ö·ç¼ÇÀ» ã°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 33¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 36¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 53¾ï 4,000¸¸ ´Þ·¯
CAGR(%) 6.70%

½ÃÀå ¼ºÀåÀº ½Å¼ÓÇÑ °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä, »õ·Î¿î À¯ÇüÀÇ ÃâÇö, ÀÇ·á ÀÎÇÁ¶ó °³¼±¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½É¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Áß¿äÇÑ ±âȸ´Â °Ë»ç Á¤È®µµ¿Í È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖ´Â AI ±â¹Ý µ¥ÀÌÅÍ ºÐ¼®°ú °°Àº Çõ½ÅÀûÀÎ ±â¼úÀÇ ÅëÇÕ¿¡ ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·áÀÇ ºÎ»óÀº PoC °Ë»ç¸¦ °¡Á¤ ȯ°æÀ¸·Î È®ÀåÇÏ¿© °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀÏ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ±×·¯³ª °ø±Þ¸Á È¥¶õ, ±ÔÁ¦ Àå¾Ö¹°, Áö¿ª¸¶´Ù ´Ù¸¥ Á¤ºÎ ½ÂÀΰú °°Àº ¹°·ù ¹®Á¦·Î ÀÎÇØ ½ÃÀå ¹ßÀüÀÌ Áö¿¬µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÀå Á¡À¯À²À» È®º¸Çϱâ À§ÇØ ¸¹Àº ¾÷üµéÀÌ °æÀï¿¡ ¶Ù¾îµé¸é¼­ °æÀïÀÌ Ä¡¿­ÇØÁö°í ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº °í°¨µµ, °íƯÀ̼º °Ë»ç¸¦ °³Ã´Çϰí, ºñ¿ë È¿À²¼ºÀ» ÃÖÀûÈ­Çϰí, »ç¿ëÇϱ⠽¬¿î ¼³°è¸¦ È®º¸ÇÏ´Â µ¥ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. µðÁöÅÐ ÅëÇÕÀ» À§ÇÑ ÇÏÀÌÅ×Å© ±â¾÷°úÀÇ Á¦ÈÞ¿Í ºÐ»ê Á¦Á¶¸¦ À§ÇÑ ÆÄÆ®³Ê½Êµµ °¡Ä¡ ÀÖ´Â Àü·«ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¿©·¯ º´¿øÃ¼¸¦ µ¿½Ã¿¡ °ËÃâÇÏ´Â ¸ÖƼÇ÷º½º °Ë»ç ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ´Â À¯¸ÁÇÑ Çõ½Å ºÐ¾ßÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº ±â¼ú ¹ßÀü°ú ÁøÈ­ÇÏ´Â ÀÇ·á ¼ö¿ä¿¡ ÈûÀÔ¾î ¿ªµ¿ÀûÀΠƯ¼ºÀ» º¸À̰í ÀÖÀ¸¸ç, ±â¾÷µéÀº º¯È­¿¡ ¹ÎøÇÏ°Ô ´ëÀÀÇØ¾ß ÇÕ´Ï´Ù. Àå±âÀûÀÎ ¼º°øÀº ¼ö¿ä º¯È­¿¡ ´ëÇÑ ÀûÀÀ·Â°ú Á¦Ç° ǰÁú°ú °ø±Þ¸Á °­ÀμºÀ» À¯ÁöÇϸ鼭 ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀ» ÃæÁ·ÇÒ ¼ö ÀÖ´Â ´É·Â¿¡ ´Þ·Á ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î ÀÎÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • PoC ½ÃÇèÀ¸·ÎÀÇ ÆÐ·¯´ÙÀÓ Àüȯ
    • Äڷγª19 È®ÁøÀÚ Áõ°¡¿¡ µû¸¥ Á¤ºÎ Áö¿ø Áõ°¡·Î Äڷγª19 °ËÁø¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø È®´ë
    • »õ·Î¿î PoC Áø´Ü ÀåºñÀÇ ½Å¼ÓÇÑ Ãâ½Ã
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÈÆ·ÃµÈ ÀÓ»ó Á÷¿øÀÌ ¾ø±â ¶§¹®¿¡ ºÐ¼®±â À¯Áöº¸¼ö°¡ º¹ÀâÇÕ´Ï´Ù.
  • ½ÃÀå ±âȸ
    • Äڷγª19¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ ¹× Á¤ºÎÀÇ Á¦Ç° ½ÂÀÎ Áõ°¡
    • PoC Áø´Ü °Ë»ç °³¹ßÀ» À§ÇÑ ¹Î°£ ¹× °ø°ø ±â°üÀÇ ÀÚ±Ý Á¶´Þ ¹× ÅõÀÚ Áõ°¡
  • ½ÃÀå °úÁ¦
    • PoC °Ë»çÀÇ ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á

Portre's Five Forces: Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå : »ùÇà 󸮺°

  • RNA ÃßÃ⠽ýºÅÛ
    • POC(Point of Care) °Ë»ç Àåºñ
    • ½Å¼Ó °Ë»ç ŰƮ
    • RT-PCR °Ë»ç

Á¦7Àå Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå »ùÇà À¯Çüº°

  • ºñ°­ ½º¿Ò
  • ºñÀεΠ½º¿Ò
  • ±¸°­ ÀεΠ½º¿Ò
  • Ÿ¾×

Á¦8Àå Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • Áø´Ü¼¾ÅÍ ¹× Ŭ¸®´Ð
  • ȨÄɾî
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Äڷγª19 °ËÃâ PoC ŰƮ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Aurora Biomed Inc.
  • Becton Dickinson and company
  • BGI Group
  • BioFire Diagnostics
  • bioMerieux SA
  • Cerba HealthCare S.A.S. by EQT
  • Co-Diagnostics, Inc.
  • Convergent Technologies GmbH & Co. KG
  • Cue health Inc.
  • DiaSorin S.p.A.
  • Drummond Scientific Company
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Quest Diagnostics
  • Quidel Corporation
  • SD Biosensor Inc.
  • Seegene, Inc
  • Thermo Fisher Scientific, Inc.
LSH 24.11.13

The COVID-19 Detection PoC Kits Market was valued at USD 3.39 billion in 2023, expected to reach USD 3.61 billion in 2024, and is projected to grow at a CAGR of 6.70%, to USD 5.34 billion by 2030.

The scope and definition of COVID-19 Detection PoC (Point-of-Care) Kits encompass their role in enabling rapid, accessible testing outside traditional laboratory settings. These kits are essential for quick identification and isolation of COVID-19 cases, facilitating real-time decision-making in diverse environments such as airports, workplaces, and medical facilities. The application scope spans from remote, under-resourced areas to urban centers, enhancing public health responses and reducing transmission. End-use markets include healthcare facilities, public health organizations, private corporations, and travel and education sectors, each seeking efficient testing solutions for managing outbreaks and ensuring safety.

KEY MARKET STATISTICS
Base Year [2023] USD 3.39 billion
Estimated Year [2024] USD 3.61 billion
Forecast Year [2030] USD 5.34 billion
CAGR (%) 6.70%

Market growth is influenced by the ongoing demand for rapid testing solutions, the emergence of new variants, and the global focus on health infrastructure improvement. A key opportunity lies in the integration of innovative technologies like AI-driven data analysis, which can enhance test accuracy and efficiency. The rise of telemedicine also presents potential for expanding PoC testing to home settings, increasing test accessibility. However, market advancement is challenged by logistical issues like supply chain disruptions, regulatory hurdles, and varying governmental approvals across regions. Furthermore, the competitive landscape is crowded, with numerous players striving for market share.

To capitalize on market opportunities, firms should focus on developing highly sensitive and specific tests, optimizing cost-effectiveness, and ensuring easy-to-use designs. Collaborations with tech companies for digital integration and partnerships for distributed manufacturing can be valuable strategies. Investing in R&D for multiplex testing-detecting multiple pathogens simultaneously-presents a promising innovation area. The market exhibits a dynamic nature, fueled by technological advancements and evolving healthcare needs, requiring businesses to remain agile and responsive to changes. Long-term success will depend on adaptability to shifts in demand and the ability to meet stringent regulatory standards while maintaining product quality and supply chain resilience.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving COVID-19 Detection PoC Kits Market

The COVID-19 Detection PoC Kits Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Paradigm shift towards PoC testing
    • Rising government support for COVID-19 detection owing to rising cases of COVID
    • Rapid launch of new PoC diagnostic devices
  • Market Restraints
    • Complex maintenance of the analyzers owing to non trained clinical staff
  • Market Opportunities
    • Increasing product approval by regulatory bodies and government testing for COVID-19
    • Increasing funding and investments by private and public organizations for the development of PoC diagnostic tests
  • Market Challenges
    • Concerns associated with adverse effect of PoC testing

Porter's Five Forces: A Strategic Tool for Navigating the COVID-19 Detection PoC Kits Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the COVID-19 Detection PoC Kits Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the COVID-19 Detection PoC Kits Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the COVID-19 Detection PoC Kits Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the COVID-19 Detection PoC Kits Market

A detailed market share analysis in the COVID-19 Detection PoC Kits Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the COVID-19 Detection PoC Kits Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the COVID-19 Detection PoC Kits Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the COVID-19 Detection PoC Kits Market

A strategic analysis of the COVID-19 Detection PoC Kits Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the COVID-19 Detection PoC Kits Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aurora Biomed Inc., Becton Dickinson and company, BGI Group, BioFire Diagnostics, bioMerieux SA, Cerba HealthCare S.A.S. by EQT, Co-Diagnostics, Inc., Convergent Technologies GmbH & Co. KG, Cue health Inc., DiaSorin S.p.A., Drummond Scientific Company, F. Hoffmann-La Roche AG, Hologic, Inc., Mylab Discovery Solutions Pvt. Ltd., Quest Diagnostics, Quidel Corporation, SD Biosensor Inc., Seegene, Inc, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the COVID-19 Detection PoC Kits Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Sample Handling, market is studied across RNA Extraction Systems. The RNA Extraction Systems is further studied across Point-Of-Care Testing Devices, Rapid Testing Kits, and RT-PCR testing.
  • Based on Sample Type, market is studied across Nasal Swabs, Nasopharyngeal Swab, Oropharyngeal Swab, and Saliva.
  • Based on End-Use, market is studied across Diagnostic Centers & Clinics, Home Care, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Paradigm shift towards PoC testing
      • 5.1.1.2. Rising government support for COVID-19 detection owing to rising cases of COVID
      • 5.1.1.3. Rapid launch of new PoC diagnostic devices
    • 5.1.2. Restraints
      • 5.1.2.1. Complex maintenance of the analyzers owing to non trained clinical staff
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing product approval by regulatory bodies and government testing for COVID-19
      • 5.1.3.2. Increasing funding and investments by private and public organizations for the development of PoC diagnostic tests
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with adverse effect of PoC testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. COVID-19 Detection PoC Kits Market, by Sample Handling

  • 6.1. Introduction
  • 6.2. RNA Extraction Systems
    • 6.2.1. Point-Of-Care Testing Devices
    • 6.2.2. Rapid Testing Kits
    • 6.2.3. RT-PCR testing

7. COVID-19 Detection PoC Kits Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Nasal Swabs
  • 7.3. Nasopharyngeal Swab
  • 7.4. Oropharyngeal Swab
  • 7.5. Saliva

8. COVID-19 Detection PoC Kits Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Clinics
  • 8.3. Home Care
  • 8.4. Hospitals

9. Americas COVID-19 Detection PoC Kits Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific COVID-19 Detection PoC Kits Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa COVID-19 Detection PoC Kits Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aurora Biomed Inc.
  • 3. Becton Dickinson and company
  • 4. BGI Group
  • 5. BioFire Diagnostics
  • 6. bioMerieux SA
  • 7. Cerba HealthCare S.A.S. by EQT
  • 8. Co-Diagnostics, Inc.
  • 9. Convergent Technologies GmbH & Co. KG
  • 10. Cue health Inc.
  • 11. DiaSorin S.p.A.
  • 12. Drummond Scientific Company
  • 13. F. Hoffmann-La Roche AG
  • 14. Hologic, Inc.
  • 15. Mylab Discovery Solutions Pvt. Ltd.
  • 16. Quest Diagnostics
  • 17. Quidel Corporation
  • 18. SD Biosensor Inc.
  • 19. Seegene, Inc
  • 20. Thermo Fisher Scientific, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦